病灶内注射贝伐单抗治疗初发翼状胬肉的临床研究  

Clinical research of intralesional bevacizumab injection on primary pterygium

作　　者：林雅娜[1] 赵晓静[1] 郑晓硕[1] 李勤[1] 

机构地区：[1]中山大学附属第五医院眼科,中国广东省珠海市519000

出　　处：《国际眼科杂志》2015年第3期555-557,共3页International Eye Science

摘　　要：目的:评价贝伐单抗注射治疗初发翼状胬肉的临床疗效及安全性。方法:选取2012-05/2013-04在我院眼科门诊就诊的初发翼状胬肉患者66例66眼随机分为两组,试验组34眼行病灶内注射贝伐单抗1.25mg/次,1次/mo,共三次,对照组32眼予人工泪液及非甾体抗炎滴眼液滴眼。结果:随访6mo,试验组与对照组胬肉充血程度及厚度均较基线水平下降,两组差异有统计学意义(P<0.05);视力、眼压、胬肉百分比与基线水平比较均无统计学差异(P>0.05)。结论:贝伐单抗病灶内注射可有效控制初发翼状胬肉至少6mo,未见明显眼部及全身并发症。AIM： To evaluate the clinical efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment.METHODS： A total of 66 patients（ 66 eyes） from May,2012 to April,2013 were randomized into 2 groups. The treatment group（ 34 eyes） was received an intralesional injection of bevacizumab 1. 25mg（ 100 mg /4mL） each time,once a month,a total of three times. The control group（ 32 eyes） was received a combination of artificial tears and non- steroidal anti- inflammatory eye drops.RESULTS： After 6mo follow- up,it was showed that there was a statistically significant reduction of injection and the elevation of pterygium was compared with the baseline in both groups（ P〈0. 05）. There was no significant difference of vision,intraocular pressure and percentage of corneal pterygium compared with the baseline in both groups（ P〉0. 05）.CONCLUSION： Intralesional bevacizumab can control primary pterygium effectively for at least 6mo with no serious ocular or systemic adverse effects.

关 键 词：贝伐单抗 翼状胬肉 初发 

分 类 号：R777.33[医药卫生—眼科]